Target intelligence / Profile preview

Major facilitator superfamily domain-containing protein 12 (MFSD12)

Target
MFSD12
Molecular classification
Transporter (specifically, a member of the major facilitator superfamily—MFS transporter), Transmembrane protein
01

Overview

Major facilitator superfamily domain-containing protein 12 (MFSD12) is a transmembrane cysteine transporter protein expressed in lysosomes and melanosomes, key for regulating melanin biosynthesis and maintaining lysosomal cysteine homeostasis. MFSD12 is essential in pigment cells for the import of cysteine, which modulates skin pigmentation via the synthesis of pheomelanin, and is also critical in non-pigmented cells for maintaining lysosomal function. Recent studies have implicated MFSD12 as an oncogenic factor in several cancers, driving cell cycle progression and tumor cell proliferation, notably in melanoma and lung adenocarcinoma. Mechanistically, MFSD12 acts upstream of PI3K/AKT signaling, and its inhibition may suppress tumor growth but could also affect normal lysosomal processes. MFSD12 is increasingly considered a potential therapeutic target and prognostic biomarker, especially in oncology and lysosomal storage disease contexts.

Other names
C19orf28PP3501SLC59B1MGC20700major facilitator superfamily domain containing 12
02

Mechanism of action

Drugs inhibiting PI3K/AKT downstream signaling can counteract MFSD12-driven cell proliferation in melanoma. In theory, potential small-molecule inhibitors of the transporter function are being considered as research advances.

03

Biological functions

Cysteine transmembrane transportRegulation of melanin biosynthesis and skin pigmentationCell cycle progression (specifically G1-to-S transition)Cell proliferation in cancerRegulation of lysosomal homeostasis
04

Disease associations

Cancer (notably melanoma, breast cancer, and lung adenocarcinoma)Lysosomal storage diseases (via cysteine/lysosomal homeostasis)Skin pigmentation disordersPotential prognostic biomarker for melanoma
05

Safety considerations

Therapeutic inhibition may risk disruption of normal lysosomal cysteine transport, affecting skin pigmentation and potential lysosomal storage homeostasisImplicated in non-apoptotic cell death (ferroptosis) if cysteine homeostasis is compromised
06

Interacting drugs

No specific drugs directly targeting MFSD12 are currently known

1 more in the full profile.

07

Biomarkers

MFSD12 expression level is a prognostic biomarker in melanoma (predicts poor survival when elevated)Cell cycle markers (CDK2, cyclin D1, and cyclin E1) are downstream of MFSD12 activation in tumor cells

Beyond the preview

Go deeper on Major facilitator superfamily domain-containing protein 12 (MFSD12).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Major facilitator superfamily domain-containing protein 12 (MFSD12).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call